| Marcus Clark, | |
|
5841 S Maryland Ave, Chicago, IL 60637-1443 | |
| (888) 824-0200 | |
| Not Available |
| Full Name | Marcus Clark |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Rheumatology |
| Location | 5841 S Maryland Ave, Chicago, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790847242 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 036087330 (Illinois) | Primary |
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.
454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.
With the overhaul continuing to be a divisive issue, lawmakers from both sides of the aisle - as well as the measure's advocates and opponents - have put in place messages and plans to keep their arguments strong.
In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.
› Verified 8 days ago
| Entity Name | The University Of Chicago Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.
454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.
With the overhaul continuing to be a divisive issue, lawmakers from both sides of the aisle - as well as the measure's advocates and opponents - have put in place messages and plans to keep their arguments strong.
In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marcus Clark, 150 Harvester Dr, Suite 300, Burr Ridge, IL 60527-5919 Ph: () - | Marcus Clark, 5841 S Maryland Ave, Chicago, IL 60637-1443 Ph: (888) 824-0200 |
News Archive
GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.
454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.
With the overhaul continuing to be a divisive issue, lawmakers from both sides of the aisle - as well as the measure's advocates and opponents - have put in place messages and plans to keep their arguments strong.
In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.
› Verified 8 days ago
Dr. Sorin C Danciu, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |